454 related articles for article (PubMed ID: 24305719)
1. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
[TBL] [Abstract][Full Text] [Related]
2. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
Kim BYS; Jiang W; Beiko J; Prabhu SS; DeMonte F; Gilbert MR; Sawaya R; Aldape KD; Cahill DP; McCutcheon IE
J Neurooncol; 2014 Jun; 118(2):405-412. PubMed ID: 24777756
[TBL] [Abstract][Full Text] [Related]
4. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
[TBL] [Abstract][Full Text] [Related]
5. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.
Jungk C; Scherer M; Mock A; Capper D; Radbruch A; von Deimling A; Bendszus M; Herold-Mende C; Unterberg A
J Neurooncol; 2016 Sep; 129(2):319-28. PubMed ID: 27344556
[TBL] [Abstract][Full Text] [Related]
7. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
8. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
[TBL] [Abstract][Full Text] [Related]
10. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between IDH1 mutation and prognosis in supratentorial high-grade astrocytomas].
Xie F; Tang JJ; Wang X; Liu YH; Mao Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 44(2):184-7, 192. PubMed ID: 23745251
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.
Waqar M; Hanif S; Brodbelt AR; Rathi N; Das K; Zakaria R; Walker C; Jenkinson MD
World Neurosurg; 2015 Jul; 84(1):154-62. PubMed ID: 25779854
[TBL] [Abstract][Full Text] [Related]
14. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
16. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the occurrence rates of
Cho U; Yang SH; Yoo C
J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
[TBL] [Abstract][Full Text] [Related]
18. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
19. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
20. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]